Glucagon-like peptide-1 receptor agonists and risk for hematologic malignancies: a multicenter propensity score-matched analysis

• by Pratik Shah, Adit Singhal, Tsu Hsien Wang, Albert Ko, Yu-Cheng Chang, Anita Ng, Andrew Shih, Yuan Ping Hsia, Cho-Hung Chiang, Cho-Han Chiang

• October 12, 2026

Parents’ Perspectives on Using Computerized Cognitive Training to Manage Cognitive Late Effects in Children With Cancer: Qualitative Descriptive Study

• by Tao Liu, Lin Mo, Feisal Hasen, Shishuang Zhou, Cho Lee Wong, XueMei Tang, Ting Han

• October 13, 2026

Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount

“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce

• October 12, 2026

• 3 min

Publisher Correction: defining global priorities in hematopoietic transplantation and cellular therapy: a statement paper from the EBMT global committee

• by Arnon Nagler, Norbert Claude Gorin, Christian Chabannon, Guillermo Puigventós, Romée Heemskerk, Isabel Sánchez-Ortega, Tuula Rintala, Yann Mahé, Emanuele Angelucci, Silvia Montoto, Michelle Kenyon, Hilda Mekelenkamp, Donal P. McLornan, Antonio M. Risitano, Mette Hazenberg, Anna Sureda, Ibrahim Yakoub Agha, Annalisa Ruggeri, Fabio Ciceri, Raffaella Greco

• October 12, 2026